P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
Niels W.C.J. van de Donk,
Alfred Garfall,
Lotfi Benboubker,
Katarina Uttervall,
Kaz Groen,
Laura Rosiñol Dachs,
Caroline Hodin,
Tara Stephenson,
Danielle Trancucci,
Alfredo Perales-Puchalt,
Rachel Kobos,
Arnob Banerjee,
Maria-Victoria Mateos
Affiliations
Niels W.C.J. van de Donk
1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Alfred Garfall
2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
Lotfi Benboubker
3 Hôpital Bretonneau, Centre Hospitalier Régionale Universitaire, Tours, France
Katarina Uttervall
4 Karolinska University Hospital, Stockholm, Sweden
Kaz Groen
1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Laura Rosiñol Dachs
5 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
Caroline Hodin
6 Janssen Research & Development BE, Antwerp, Belgium
Tara Stephenson
7 Janssen Research & Development, Spring House, United States
Danielle Trancucci
8 Janssen Research & Development, Raritan, United States
Alfredo Perales-Puchalt
7 Janssen Research & Development, Spring House, United States
Rachel Kobos
8 Janssen Research & Development, Raritan, United States
Arnob Banerjee
7 Janssen Research & Development, Spring House, United States
Maria-Victoria Mateos
9 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
